[go: up one dir, main page]

AR084234A1 - PREDICTIVE METHODS AND METHODS TO TREAT ARTHRITIS USING INTERLEUQUINE ANTAGONISTS 17 (IL-17) - Google Patents

PREDICTIVE METHODS AND METHODS TO TREAT ARTHRITIS USING INTERLEUQUINE ANTAGONISTS 17 (IL-17)

Info

Publication number
AR084234A1
AR084234A1 ARP110104621A ARP110104621A AR084234A1 AR 084234 A1 AR084234 A1 AR 084234A1 AR P110104621 A ARP110104621 A AR P110104621A AR P110104621 A ARP110104621 A AR P110104621A AR 084234 A1 AR084234 A1 AR 084234A1
Authority
AR
Argentina
Prior art keywords
methods
interleuquine
antagonists
predictive
treat arthritis
Prior art date
Application number
ARP110104621A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR084234A1 publication Critical patent/AR084234A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente acta se dirige a métodos predictivos y terapias personalizadas para tratar la artritis reumatoide (RA). Específicamente, la presente se relaciona con predecir la probabilidad de que un paciente con artritis reumatoide responderá clínicamente al tratamiento con una molécula de enlace de IL-17, por ejemplo, un anticuerpo de IL-17, tal como secukinumab.This act is aimed at predictive methods and personalized therapies to treat rheumatoid arthritis (RA). Specifically, this is related to predicting the probability that a patient with rheumatoid arthritis will respond clinically to treatment with an IL-17 binding molecule, for example, an IL-17 antibody, such as secukinumab.

ARP110104621A 2010-12-13 2011-12-12 PREDICTIVE METHODS AND METHODS TO TREAT ARTHRITIS USING INTERLEUQUINE ANTAGONISTS 17 (IL-17) AR084234A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42252110P 2010-12-13 2010-12-13

Publications (1)

Publication Number Publication Date
AR084234A1 true AR084234A1 (en) 2013-05-02

Family

ID=45390221

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104621A AR084234A1 (en) 2010-12-13 2011-12-12 PREDICTIVE METHODS AND METHODS TO TREAT ARTHRITIS USING INTERLEUQUINE ANTAGONISTS 17 (IL-17)

Country Status (3)

Country Link
AR (1) AR084234A1 (en)
TW (1) TW201307845A (en)
WO (1) WO2012082573A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603193A (en) 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
TWI618543B (en) 2010-11-05 2018-03-21 諾華公司 Use of IL-17 antibody for the preparation of a medicament for treating ankylosing spondylitis
EP2783014A1 (en) * 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1212214A1 (en) * 2012-08-31 2016-06-10 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
BR112016029460A2 (en) 2014-06-23 2017-10-24 Five Prime Therapeutics Inc Methods To Treat Rheumatoid Arthritis
LT3191120T (en) 2014-09-10 2024-07-25 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
EA036261B1 (en) 2014-10-29 2020-10-20 Файв Прайм Терапьютикс, Инк. Combination therapy for cancer
EP3237447B1 (en) 2014-12-22 2020-12-02 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
AR103172A1 (en) * 2014-12-22 2017-04-19 Novartis Ag SELECTIVE REDUCTION OF CYSTEINE WASTE IN ANTIBODIES IL-17
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
PT3283527T (en) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc COMBINATION THERAPEUTIC FOR CANCER
JP2020535119A (en) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク Combination therapy of anti-CSF1R and anti-PD-1 antibody for pancreatic cancer
TW202539734A (en) 2019-09-20 2025-10-16 瑞士商諾華公司 Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AU2007235199B8 (en) 2006-01-31 2010-10-28 Novartis Ag IL-17 antagonistic antibodies for treating cancer
NZ591484A (en) * 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof

Also Published As

Publication number Publication date
TW201307845A (en) 2013-02-16
WO2012082573A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
AR084234A1 (en) PREDICTIVE METHODS AND METHODS TO TREAT ARTHRITIS USING INTERLEUQUINE ANTAGONISTS 17 (IL-17)
MX2024015844A (en) Agonist antibodies that bind human cd137 and uses thereof
CY1122978T1 (en) ANTI-VLA-4 ANTIBODIES
UY33407A (en) SPECIFIC ANTIBODIES OF THE HUMAN GDF8 FACTOR
EA201400254A1 (en) BISPECIFIC ANTIGENSIVE-BONDING MOLECULES ACTIVATING T-CELLS
EA201300978A1 (en) ANTIBODIES TO CEA
CL2013001213A1 (en) Antibody for interleukin 17 (il-17); Use this to treat rheumatoid arthritis.
MY163539A (en) Antibody fc variants
EA201500876A1 (en) BISPECIFIC ANTIGENSIVE-BONDING MOLECULES ACTIVATING T-CELLS
MX358541B (en) Methods for predicting risk of developing hypertension.
EA201301208A1 (en) NEW IMMUNOCONJUGATES
MX341884B (en) Anti-bcma antibodies.
MX2013009362A (en) Antibody against the csf-1r.
MX391802B (en) Anti-aging antibodies for the treatment of inflammation and autoimmune disorders
ECSP13013084A (en) USE OF ANTI-CD19 ANTIBODY IMMUNOCATED WITH MAITANSINOID FOR THE TREATMENT OF SYMPTOM TUMORS OF CELLS B
MX2013009679A (en) Anti-il-6 receptor antibodies and methods of use.
EA201400875A1 (en) ANTIBODIES TO CD47 AND METHODS OF THEIR APPLICATION
AR061568A1 (en) COMPOUNDS
MX349095B (en) Bispecific antigen binding molecules.
EA201690213A1 (en) COMPOSITIONS AND METHOD FOR TREATMENT OF CONNECTED STATES
MX2014006158A (en) Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles.
CR20110559A (en) SPECIFIC ANTIBODIES FOR CADHERINA-17
CR20150153A (en) TREATMENT FOR REUMATOID ARTITRIS
BR112013032871A8 (en) HOST BACTERIAL STRAIN EXPRESSING RECOMBINANT DSBC AND METHOD FOR PRODUCING ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF IT THAT SPECIFICALLY BINDS TO CD154
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy

Legal Events

Date Code Title Description
FA Abandonment or withdrawal